Common use of Purchase Warrant Clause in Contracts

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 (the “Commencement Date”), and at or before 5:00 p.m., New York City time, [____________]2 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereof. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC ARATANA THERAPEUTICS, INC. or its assigns (“Holder”), as registered owner of this Purchase Warrant, BioVie to Advaxis, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 March 19, 2014 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 March 19, 2024 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 153,061 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 4.90 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC (“Holder”), as registered owner of this Purchase Warrant, BioVie to InspireMD, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [September ________________]1 , 2016 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [March ____________]2 , 2021 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] _________ shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 0.7375 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC ▇▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC. (“Holder”), as registered owner of this Purchase Warrant, BioVie to Biocept Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning June 5, 2018 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 December 5, 2022 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 246,250 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 0.85 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC U.S. Tiger Securities, Inc. (“Holder”), as registered owner of this Purchase WarrantWarrant of Stran & Company, BioVie Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 May 12, 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 November 12, 2026 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 14,964 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 5.1875 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______November 8, 2025]2021, the date on which the Registration Statement on Form S-1 (File No. 333-[*]333-260109) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to CleanCore Solutions, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning April 30, 2024 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 April 25, 2029 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 87,500 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 5.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (“Holder”)Boustead Securities, LLC, as registered owner of this Purchase WarrantWarrant (“Holder”), BioVie to Signing Day Sports, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning November 16, 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 November 13, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 84,000 shares (the “Shares”) of common stock of the Company, $0.0001 par value $0.0001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 6.75 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC (“Holder”), as registered owner of this Purchase Warrant, BioVie to InspireMD, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [September ________________]1 , 2016 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [March ____________]2 , 2016 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] ______ shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 0.7375 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC. (“Holder”), as registered owner of this Purchase Warrant, BioVie to Sigma Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 October 6, 2018 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 October 6, 2023 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] ________________ shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ________________ per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Moving iMage Technology, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2020 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 20251 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2027[1] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 [2] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Aditx Therapeutics, Inc, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning February [________________●]1 , 2021 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 20251 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] ]2 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning Septemeber 20, 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 September 15, 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 289,800 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 2.40 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc., to Acesis Holdings Corporation a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________*]1 , 2023 (the “Commencement Issue Date”), and at or before 5:00 p.m., New York City Eastern time, [____________*]2 , 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●*] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 *] per ShareShare1; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 20271 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 2 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc.to PARETEUM CORP., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________●]1 , 2018 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2022 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly One Hundred Dollars ($100) paid by or on behalf of ThinkEquity LLC [__________] (“Holder”), as registered owner of this Purchase Warrant, BioVie to iSign Solutions Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 May 16, 2017 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 May 16, 2021 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●_________] shares of the common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 2.175 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Shuttle Pharmaceuticals Holdings, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 20271 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Hempacco Co., Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning September 1, 2022 (the “Commencement Issue Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 August 29, 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 70,000 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 9.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Arch Therapeutics, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2024 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, BioVie to Alset EHome International Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2021 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2023 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC YA II PN, LTD. (“Holder” or “YA II”), as registered owner of this Purchase Warrant, BioVie to Micronet Enertec Technologies, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 October 28, 2016 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 October 28, 2021 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 66,000 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this the Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 3.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC ________________ (“Holder”), as registered owner of this Purchase Warrant, BioVie to Advaxis, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 March 26, 2015 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 March 26, 2019 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] _________ shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this the Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 3.75 per ShareShare (125% of the price of the Shares sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc.to RiT Technologies Ltd., a Nevada corporation company formed under the laws of the State Israel (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 ] [DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 ] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●____] [5% of Shares sold in Offering excluding over allotment] ordinary shares of common stock of the Company, par value $0.0001 NIS 0.80 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereof. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrantherein. This Purchase Warrant is initially exercisable at $[●]3 ___] per Share; provided, however, that upon the occurrence of any Share [125% of the events specified price of the Shares sold in the Offering]; subject to adjustment pursuant to Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc.to Turbo Energy, S.A., a Nevada Spanish corporation with limited liability organized under the laws of Spain (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning September 26, 2023 (the “Commencement Issue Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 September 20, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 per share American Depositary Shares (the “Shares”), each Share representing five (5) ordinary shares of the Company, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 6.25 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by the payment of $100.00 and for other good and value consideration, Aegis Capital Corp. or on behalf of ThinkEquity LLC its assigns (“Holder”), as registered owner of this Purchase Warrant, BioVie to CVSL Inc., a Nevada Florida corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 , 2016 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 , 2020 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●____] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ___] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Cadrenal Therapeutics, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________beginning [ ]1 , 2022 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________[ ]2 , 20271 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●[ ] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 [ ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning September 29, 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 September 26, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 980,000 shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 0.25 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC WESTPARK CAPITAL, INC. (“Holder”), as registered owner of this Purchase Warrant, BioVie to NeurMedix, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2018 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2023 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.000001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC. (“Holder”), as registered owner of this Purchase Warrant, BioVie to Sigma Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 November 7, 2019 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 November 7, 2024 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] ________________ shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ________________ per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 August 11, 2025 (the “Commencement Date”), and at or before 5:00 p.m., New York City time, [____________]2 August 11, 2030 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereof. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 2.50 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______August 7, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]333-288525) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC A.G.P./Alliance Global Partners (“Holder”), as registered owner of this Purchase Warrant, BioVie to Cocrystal Pharma, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 ] (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 ] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●____] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ___] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC D▇▇▇▇▇ ▇▇▇▇▇ SECURITIES, INC (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc.to PARETEUM CORP., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________●]1 , 2018 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2022 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [__] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Sidus Space, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning March [________________]1 , 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, March [____________]2 , 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] ____]1 shares of Class A common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●___]3 2 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Digital Offering, LLC (the “Holder” or “Digital Offering”), as registered owner of this Purchase Warrant, BioVie to Autonomix Medical, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________*]1 , 2023 (the “Commencement Effective Date”), and at or before 5:00 p.m., New York City Eastern time, [____________*]2 , 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●*] shares of common stock Common Stock of the Company, $0.01 par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 6.25 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Hempacco Co., Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________*]1 , 2023 (the “Commencement Issue Date”), and at or before 5:00 p.m., New York City Eastern time, [____________*]2 , 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●*] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 *] per ShareShare1; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC YA II PN, LTD. (“Holder” or “YA II”), as registered owner of this Purchase Warrant, BioVie to Micronet Enertec Technologies, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 December 22, 2016 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 December 22, 2021 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 120,000 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this the Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 3.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Moving iMage Technologies, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning July 12, 2021 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 July 7, 2026 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 241,500 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 3.75 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity The Benchmark Company, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning September 29, 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 September 26, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 980,000 shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 0.25 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Mangoceuticals, Inc., a Nevada Texas corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2028 1 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per ShareShare 2; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie Inc.to Genelux Corporation, a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning [________________●]1 , 202[3] (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 1 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Cadrenal Therapeutics, Inc., a Nevada Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning January 19, 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 January 19, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 84,000 shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 6.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity ▇▇▇▇▇▇ ▇▇▇▇▇▇ & Co., LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Maverick Lifestyle Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time beginning six months from [________________]1 (the “Commencement Date”)Effective Date , and at or before 5:00 p.m., New York City Eastern time, [____________●]2 , 202_4 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of Class A common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 ] per ShareShare5; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, BioVie to Mangoceuticals, Inc., a Nevada Texas corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________]1 beginning March 20, 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, [____________]2 March 20, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 87,500 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 5.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of ThinkEquity LLC [●] (“Holder”), as registered owner of this Purchase Warrant, BioVie to Know Labs, Inc., a Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from beginning September [________________●]1 , 2023 (the “Commencement Date”), and at or before 5:00 p.m., New York City Eastern time, September [____________●]2 , 20281 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereofherein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]3 2 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [_______, 2025], the date on which the Registration Statement on Form S-1 (File No. 333-[*]) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).